To determine the translational significance of the above findings, we first analyzed the relationship between the expression of a pyroptotic gene signature in tumors and the clinical response to immune checkpoint blockade in one cohort of metastatic melanoma patients treated with an anti-CTLA4 blocking antibody. The gene discussed is CTLA4; the disease is metastatic melanoma.